Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10601259 | 0.98 | HTR6 (0.56) | HTR6PNMTHTR7HTR2ADPP4 | |
| Acetic Acid SCHEMBL27542286 | 0.88 | HTR6 (0.47) | HTR6PNMTHTR7MAOATSHR | |
| SCHEMBL31547775 | 0.83 | HTR6 (0.59) | HTR6PNMTHTR7HTR2ACYP2A6 | |
| SCHEMBL3862943 | 0.83 | HTR6 (0.59) | HTR6PNMTHTR7HTR2ACYP2A6 | |
| SCHEMBL2338975 | 0.82 | HTR6 (0.56) | HTR6HTR7MAOAMAOBCES1 | |
| SCHEMBL7618202 | 0.82 | HTR6 (0.67) | HTR6HTR7HTR2ACYP2A6MAOA | |
| SCHEMBL31121639 | 0.82 | HTR6 (0.56) | HTR6HTR7MAOAMAOBCES1 | |
| SCHEMBL6683873 | 0.80 | HTR6 (0.51) | HTR6PNMTHTR7HTR2AMAOA | |
| SCHEMBL29446311 | 0.79 | SIGMAR1 (0.46) | HTR6PNMTHTR2ACYP2A6MAOA | |
| SCHEMBL9379776 | 0.79 | SIGMAR1 (0.46) | HTR6PNMTHTR2ACYP2A6MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105654-A | Curable resin mixture, curable resin composition, and cured product thereof | 日本化药株式会社 | 2020-12-18 | — | — | CN | disclosed |
| WO-2020031935-A1 | CURABLE RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT | 日本化薬株式会社 | 2020-02-13 | — | — | WO | disclosed |
| US-8986938-B2 | Microbial activity improvement agent, microbial activity improvement method, and biological waste treatment method | SUMITOMO HEAVY INDUSTRIES, LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | US | disclosed |
| US-8309596-B2 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2012-11-13 | — | — | US | disclosed |
| US-20120107914-A1 | MICROBIAL ACTIVITY IMPROVEMENT AGENT, MICROBIAL ACTIVITY IMPROVEMENT METHOD, AND BIOLOGICAL WASTE TREATMENT METHOD | SUMITOMO HEAVY INDUSTRIES, LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20100256144-A1 | Kallikrein 7 modulators | NOVARTIS AG (CH) | 2010-10-07 | — | — | US | disclosed |
| CN-1263745-C | Aryl fused azapolycyclic compounds | PFIZER PROD INC (US) | 2006-07-12 | — | — | CN | disclosed |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| CN-1406227-A | aryl fused azapolycyclic compounds | PFIZER PROD INC (US) | 2003-03-26 | — | — | CN | disclosed |
| US-4791103-A | HYPOTENSIVE AGENTS, PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0179667-A2 | N6-substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028843-A1 | KALLIKREIN 7 MODULATORS | KLK7, KLK5, KLKB1 | HTR6 2237/4885PNMT 3728/4885HTR7 381/4885 |
| US-20040225130-A1 | Imidazolyl derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | HTR6 102/4885PNMT 1024/4885HTR7 95/4885 |
| US-20100256144-A1 | Kallikrein 7 modulators | KLK7, KLK5, KLKB1 | HTR6 2237/4885PNMT 3728/4885HTR7 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.